Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of PEGPH20 and Pembrolizumab (MK-3475) for Patients With Previously Treated Hyaluronan High (HA-High) Metastatic Pancreatic Ductal Adenocarcinoma

NCT03634332 is registered in ClinicalTrials.gov with Pancreatic Cancer Research Team as lead sponsor.

NCT NCT03634332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03634332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of PEGPH20 and Pembrolizumab (MK-3475) for Patients With Previously Treated Hyaluronan High (HA-High) Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Pancreatic Cancer Research Team
Phase
Phase 2
Overall status
Unknown status
Start date
May 1, 2019
Completion date
January 31, 2021
Enrollment
35 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pancreatic ductal adenocarcinoma, pancreatic neoplasms